The IL-23 inhibitor guselkumab has been shown to be effective in psoriatic arthritis patients including those who are biologic-naive or been previously treated with one or two anti-TNFs. The DISCOVER trials, published in The Lancet, showed treatment with guselkumab improved the primary outcome of ACR20 and a number of secondary outcomes including skin and joint ...
Guselkumab inhibition of the IL-23 p19 subunit effective in PsA
By Mardi Chapman
24 Mar 2020